A New Rapid Test to End COVID
Despite 93.1% to 95.8% of the UK adult population having been vaccinated and currently 83.5% to 89.8% of adults having received at least two doses (1), and despite many households testing twice a week with lateral flow tests (2), R at the time of writing is 0.9 to 1.1, with a growth rate range for England of between -1% and +1% (3). Furthermore, up to 30% of infected individuals are going on to experience Long Covid (4). The crisis is far from over and as new variants of concern like Omicron spread, the situation is not under control, even in the highly vaccinated and tested UK and far less so in many countries. The problem is likely to be replicated in other countries with currently low infection levels as isolation is eased in future, even if these countries reach a high level of vaccination. Additionally, concerns have been raised about fall in immunity by 6 months after receiving the Pfizer and AstraZeneca vaccines (5), and the ability of Omicron to re-infect and cause illness in vaccinated people, with urgent booster jabs now being given to attempt to mitigate this. A solution to stop the spread of all variants of COVID-19 is needed now, and we present it here: CLDC, a rapid test that is 98%+ sensitive, low cost and scalable..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
arXiv.org - (2021) vom: 05. Dez. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Baker, Mark Ralph [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
XAR033161178 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XAR033161178 | ||
| 003 | DE-627 | ||
| 005 | 20230429070239.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211207s2021 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)XAR033161178 | ||
| 035 | |a (arXiv)2112.02592 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Baker, Mark Ralph |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a A New Rapid Test to End COVID |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Despite 93.1% to 95.8% of the UK adult population having been vaccinated and currently 83.5% to 89.8% of adults having received at least two doses (1), and despite many households testing twice a week with lateral flow tests (2), R at the time of writing is 0.9 to 1.1, with a growth rate range for England of between -1% and +1% (3). Furthermore, up to 30% of infected individuals are going on to experience Long Covid (4). The crisis is far from over and as new variants of concern like Omicron spread, the situation is not under control, even in the highly vaccinated and tested UK and far less so in many countries. The problem is likely to be replicated in other countries with currently low infection levels as isolation is eased in future, even if these countries reach a high level of vaccination. Additionally, concerns have been raised about fall in immunity by 6 months after receiving the Pfizer and AstraZeneca vaccines (5), and the ability of Omicron to re-infect and cause illness in vaccinated people, with urgent booster jabs now being given to attempt to mitigate this. A solution to stop the spread of all variants of COVID-19 is needed now, and we present it here: CLDC, a rapid test that is 98%+ sensitive, low cost and scalable. | ||
| 700 | 1 | |a Conway, Fleur |e verfasserin |4 aut | |
| 700 | 1 | |a Ben, Filippo Dal |e verfasserin |4 aut | |
| 700 | 1 | |a Hawthorne, Elizabeth Lucinda |e verfasserin |4 aut | |
| 700 | 1 | |a Iacoviello, Licia |e verfasserin |4 aut | |
| 700 | 1 | |a Agodi, A |e verfasserin |4 aut | |
| 700 | 1 | |a Mukhtar, Saquib |e verfasserin |4 aut | |
| 700 | 1 | |a Phan, Hai |e verfasserin |4 aut | |
| 700 | 1 | |a Rabvukwa, Yemurai |e verfasserin |4 aut | |
| 700 | 1 | |a Rogge, Jessica R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t arXiv.org |g (2021) vom: 05. Dez. |
| 773 | 1 | 8 | |g year:2021 |g day:05 |g month:12 |
| 856 | 4 | 0 | |u https://arxiv.org/abs/2112.02592 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XAR | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 05 |c 12 | ||
| 953 | |2 045F |a 570 | ||